The committee made a new recommendation referring to the NICE diagnostics guidance on placental growth factor (PlGF) testing as this is applicable to women with gestational hypertension. The committee were aware of the link between gestational hypertension and both pre- existing and gestational diabetes, therefore they made an overarching recommendation at the beginning of the guideline to cross-refer to the existing NICE guideline on diabetes in pregnancy. There was no evidence on fetal monitoring in gestational hypertension, so the committee made a research recommendation. How the recommendations might affect practice The recommendations reflect current clinical practice in many units, but may help standardise practice across the NHS for units that currently use other blood pressure targets. Full details of the evidence and the committee's discussion are in evidence review B: monitoring gestational hypertension. Return to recommendations Assessment of women with pre-eclampsia Why the committee made the recommendations The committee agreed, based on their clinical expertise, that women with pre-eclampsia should have a full clinical assessment at every antenatal appointment and should be admitted to hospital if there are any concerns about the wellbeing of the woman or her baby. The committee agreed that this would include (but was not limited to) reasons such as severe hypertension or other features of pre-eclampsia indicating increased risk of adverse outcomes. There was some evidence that the fullPIERS and PREP-S models can help identify women at different risks of adverse outcomes because of pre-eclampsia. There was more extensive validation of the fullPIERS model, and the validation studies were conducted in populations from a range of healthcare settings. The PREP-S model had been developed using a UK population, and validated using data from similar multinational settings. 